The BRAF agents are different and there is good reason to hope for promising results trying another. I agree the MEK is a different pathway than the BRAF so indeed may result in a good response not found the first time with BRAF. This is all new territory and you folks will be the pioneers! Hope to learn more at ASCO, which starts tomorrow.n Stay tuned.
My husband was on Zelboraf from November last year until a couple of weeks ago – it was amazing he improved immediately. However, the cancer has now become resistant to the Z and his mets in his peritoneum/omentum are developing at an alarming rate. He has also got the ascites back which is very debilitating. He was due to start Yervoy this week but his oncologist says he is not well enough and even if he managed the first dose it is unlikely he would last the course, he has both a high red and white cell count and is dehydrated from the ascites. We are in the UK so Dabrafenib is not yet licensed here. I am trying to get him on a trial in London even though he does not meet their criteria. This is for Dabrafenib with Trametinib. I have no idea if they will accept him, this is our last hope. Do you think that after failing with Zelboraf there is any chance that this would work?
It is possible. Also, after being off zelboraf and reinducting it is a possibility. What happens is the tumor gets smart with the braf drugs but after being off it for a while, sometimes you can fool the tumor again.
Viewing 6 posts - 1 through 6 (of 6 total)
The forum ‘Melanoma Diagnosis: Stage IV’ is closed to new topics and replies.